Global Pharmaceutical CDMO Competitive Landscape Professional Research Report 2024

Global Pharmaceutical CDMO Competitive Landscape Professional Research Report 2024

Research Summary

A Pharmaceutical Contract Development and Manufacturing Organization (CDMO) is a specialized service provider that offers comprehensive support to pharmaceutical and biotechnology companies in the development, manufacturing, and commercialization of drug products. CDMOs serve as strategic partners, providing expertise and infrastructure for various stages of the drug development process, including formulation development, analytical testing, clinical trial manufacturing, and commercial-scale production. These organizations play a crucial role in the pharmaceutical industry by offering flexible and cost-effective solutions, enabling companies to outsource specific aspects of their drug development and manufacturing processes. Pharmaceutical CDMOs contribute to accelerating time-to-market, reducing development costs, and ensuring compliance with regulatory standards, allowing pharmaceutical companies to focus on research, innovation, and core competencies.

According to DIResearch's in-depth investigation and research, the global Pharmaceutical CDMO market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Pharmaceutical CDMO include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, Pfizer CentreOne, Delpharm, Recipharm, AGC Pharma Chemicals, Boehringer Ingelheim, Vetter, Curia, Aenova, Porton, Piramal, Strides Pharma, NextPharma, Famar, Jubilant, Alcami, Euroapi, Eurofins, Avid Bioservices, BioVectra, CPL etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Pharmaceutical CDMO. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Pharmaceutical CDMO market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Pharmaceutical CDMO market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Pharmaceutical CDMO industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Pharmaceutical CDMO Include:

Lonza

Catalent

Thermo Fisher Scientific

Samsung Biologics

Fareva

WuXi AppTech

WuXi Biologics

Siegfried

FUJIFILM Diosynth Biotechnologies

Asymchem

Pfizer CentreOne

Delpharm

Recipharm

AGC Pharma Chemicals

Boehringer Ingelheim

Vetter

Curia

Aenova

Porton

Piramal

Strides Pharma

NextPharma

Famar

Jubilant

Alcami

Euroapi

Eurofins

Avid Bioservices

BioVectra

CPL

Pharmaceutical CDMO Product Segment Include:

API CDMO

FDF CDMO

Packaging CDMO

Clinical CDMO

Pharmaceutical CDMO Product Application Include:

Chemical Pharmaceutical

Biopharmaceutical

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Pharmaceutical CDMO Industry PESTEL Analysis

Chapter 3: Global Pharmaceutical CDMO Industry Porter’s Five Forces Analysis

Chapter 4: Global Pharmaceutical CDMO Major Regional Market Size and Forecast Analysis

Chapter 5: Global Pharmaceutical CDMO Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Pharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Pharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Pharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Pharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Pharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Pharmaceutical CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Pharmaceutical CDMO Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources